Takeda awaits FDA approval for febuxostat, treatment for gout

NEW YORK A drug by Takeda Pharmaceutical for treating gout does not increase the risk of heart disease, a Food and Drug Administration official said Thursday.

Takeda wants approval for the drug febuxostat as a treatment for gout, particularly in patients with uric acid buildup.

Takeda, which has sought approval for the drug since 2004, plans to present data from a new trial at a meeting with the FDA Monday.